Public Company Healthcare

Leica Biosystems

Wetzlar, Germany

Leica Biosystems is a Danaher company providing pathology solutions for cancer diagnostics and workflow, including automated staining, imaging, and pathology workflow technologies.

Focus Areas
Anatomical pathology, Automated tissue staining, Digital pathology / pathology imaging

Tracked deals

3

3 tracked deals across 2022-2026.

Recent pace

2

2 tracked deals announced in the last 12 months.

Deal mix

Buyout

3 buyout

Leica Biosystems Acquisition Volume by Year

Last 2 years

Acquisition volume by year Annual acquisition counts for the last 2 years for Leica Biosystems. 1 2022 ~2 est. 2 2026
Actual Full-year estimate

Supporting Data

Recent Transactions

  • Leica Biosystems Acquires StatLab Medical Products
    September 28, 2026
    Buyer
    Leica Biosystems
    Target
    StatLab Medical Products
    Seller
    Linden Capital Partners, Audax Private Equity
    Industry
    Medical Devices
    Location
    Texas, United States
    Type
    Buyout

    Leica Biosystems, a Danaher company, completed its acquisition of StatLab Medical Products from Linden Capital Partners and Audax Private Equity on September 28, 2026. StatLab’s pre-analytical pathology consumables and equipment add specimen collection and preparation capabilities to Leica Biosystems’ pathology portfolio, broadening its offering from specimen collection through digital imaging and AI-enabled diagnosis.

  • Leica Biosystems to Acquire StatLab Medical Products From Linden Capital Partners and Audax Private Equity
    July 14, 2026
    Buyer
    Leica Biosystems
    Target
    StatLab Medical Products
    Seller
    Linden Capital Partners, Audax Private Equity
    Industry
    Medical Devices
    Location
    Texas, United States
    Type
    Buyout

    Leica Biosystems, a Danaher company, signed a definitive agreement to acquire StatLab Medical Products. StatLab is currently owned by Linden Capital Partners and Audax Private Equity, and the transaction is subject to customary closing conditions. Financial terms were not disclosed and the deal was expected to close by the end of 2026.

  • Leica Biosystems Acquires Cell IDx
    November 8, 2022
    Buyer
    Leica Biosystems
    Target
    Cell IDx
    Industry
    Biotechnology
    Location
    California, United States
    Type
    Buyout

    Leica Biosystems has acquired Cell IDx, a San Diego-based leader in multiplexed tissue profiling, integrating Cell IDx's UltraPlex multiplex IHC technology with Leica's BOND RX automation to expand translational research and multiplexing capabilities. The deal advances Leica's research-focused staining and imaging portfolio and brings scale-up and medical/scientific affairs support for Cell IDx customers.

Related Acquisition Pages

Medical Devices Buyers & Acquisitions 2 tracked deals by Leica Biosystems. Biotechnology Buyers & Acquisitions 1 tracked deal by Leica Biosystems. Acquisitions in Texas 2 tracked deals by Leica Biosystems. Acquisitions in California 1 tracked deal by Leica Biosystems.

Related articles

Selling a company? Get in front of buyers like Leica Biosystems

Turn tracked acquisition activity into an outreach-ready buyer list.

Find buyers like these →